Compare Virgin Galactic Holdings, Inc. (SPCE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.88 (market cap $445.69M), while State Street SPDR S&P Biotech ETF trades at $149.89 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 22.7× Virgin Galactic Holdings, Inc.'s market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Virgin Galactic Holdings, Inc. for 69 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| SPCE | XBI | |
|---|---|---|
Market Cap | $445.69M | $10.11B |
Volume | 5,128,850 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $7.52 | $169.55 |
52-Week Low | $2.17 | $104.99 |
Typical Hold Time | 69 Days | 37 Days |
Enterprise Value | $409.68M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Virgin Galactic (SPCE) trades at $3.01, down 1.95% on the day, reflecting ongoing investor skepticism despite recent earnings beats. The company continues to burn cash with negative operating cash flow of $240.14 million in 2025 and deeply negative profit margins. Technical indicators show a bearish trend with the stock trading near key support levels. Recent news highlights management's guidance for positive cash flow by 2027 but also a delay in commercial Delta flights to February 2027.
The outlook remains highly speculative with significant execution risk. While strong ticket demand provides a potential catalyst, the path to profitability is long and dependent on successful commercial spaceflight operations. Investors face substantial dilution risk and high volatility in this pre-revenue growth phase. The stock represents a high-risk, high-reward opportunity suitable only for risk-tolerant investors.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
